Drug intelligence / Profile preview

Human primary Retinal Pigment Epithelial cells

Development stage: Phase 1
Lead developer: Jiangsu Aierkang Biomedical Technology
Modality: Cell Therapies
Administration: Subretinal

Overview

Human primary Retinal Pigment Epithelial (HuRPE) cells are a biological intervention being investigated for the treatment of retinal degenerative diseases such as Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA). Developed by Eyecure Therapeutics Inc., this cell therapy involves the subretinal transplantation of these cells, aiming to replace or support the function of damaged retinal pigment epithelial cells in affected patients.

Beyond the preview

Go deeper on Human primary Retinal Pigment Epithelial cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human primary Retinal Pigment Epithelial cells.

Explore the full profile